[ad_1] Galapagos has found a buyer for its once-promising JAK inhibitor Jyseleca (filgotinib), signing a letter of intent to transfer the drug and related operations to Alfasigma of Italy. Under the deal, Galapagos…
Tag: Galapagos
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
[ad_1] Galapagos NV Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve the Jyseleca® (filgotinib) business and a…
UK fund giant L&G bets on Ecuador’s Galápagos debt experiment
[ad_1] The UK’s largest asset manager Legal & General has thrown its weight behind a landmark debt deal by Ecuador, in a sign of growing investor interest in swaps that…
French food group Galapagos sells shares in Alpina Savoie owner
[ad_1] Les Crozets from Alpina Savoie /credit: Alpina Savoie Facebook/ Galapagos is offloading its stake in fellow French food group Aster Développement – the holding company behind Alpina Savoie and…
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
[ad_1] GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is…
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
[ad_1] Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to…